塞利尼索在非多发性骨髓瘤血液肿瘤中的应用及研究进展  

Application and Research Progress of Selinexor in Hematologic Tumors Other Than Multiple Myeloma

作　　者：肖植文 齐凌[1,2,3] 李菲 XIAO Zhi-Wen;QI Ling;LI Fei(Department of Hematology,The First Affiliated Hospital of Nanchang University;Jiangxi Clinical Research Center for Blood Disease;Institute of Lymphatic Tumor Diseases of Nanchang Univerity,Nanchang 330006,Jiangxi Province,China)

机构地区：[1]南昌大学第一附属医院血液病诊治中心 [2]江西省血液病临床医学研究中心 [3]南昌大学淋巴肿瘤疾病研究所,江西南昌330006

出　　处：《中国实验血液学杂志》2024年第4期1295-1299,共5页Journal of Experimental Hematology

基　　金：江西省自然科学基金重点项目(20192ACB20030);江西省科技创新基地计划(20212BCG74001);中央引导地方科技发展专项(20111ZDG02006)。

摘　　要：核输出蛋白1(XPO1)是数百种蛋白质的主要转运蛋白。塞利尼索是第一代XPO1抑制剂,目前在多发性骨髓瘤的治疗中获得了较多的关注,同时最新临床试验也证实,无论是单药还是联合其他化疗方案,塞利尼索在白血病、淋巴瘤中同样能取得较好的治疗效果。本文总结了塞利尼索治疗非多发性骨髓瘤血液肿瘤的临床前研究和临床试验结果,旨在探讨未来如何选择塞利尼索单药或联合其他方案进行诱导化疗。Exportin-1(XPO1)is a major transporter for hundreds of proteins.Selinexor is the first generation XPO1 inhibitor.At present,selinexor has gained more attention in the application of multiple myeloma(MM).Meanwhile,the latest clinical trials have confirmed that whether it is a single agent or combined with other chemotherapy regimens,selinexor can also achieve good therapeutic effects in patients with leukemia and lymphoma.This review summarizes the results of preclinical studies and clinical trials of selinexor in treatment of non-MM hematological malignancies,aiming to explore how to choose single agent or in combination with other regimens as induction chemotherapy.

关 键 词：塞利尼索 白血病 非霍奇金淋巴瘤 骨髓增生异常综合征 骨髓增殖性肿瘤 

分 类 号：R733[医药卫生—肿瘤]